Shanxi C&Y Pharmaceutical Group Co Ltd - Asset Resilience Ratio

Latest as of September 2020: 0.26%

Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has an Asset Resilience Ratio of 0.26% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Shanxi C&Y Pharmaceutical Group Co Ltd (300254) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥5.00 Million

≈ $731.66K USD Cash + Short-term Investments

Total Assets

CN¥1.91 Billion

≈ $279.34 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2014)

This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See 300254 net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Shanxi C&Y Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300254 market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥5.00 Million	0.26%
Total Liquid Assets	CN¥5.00 Million	0.26%

Asset Resilience Insights

Limited Liquidity: Shanxi C&Y Pharmaceutical Group Co Ltd maintains only 0.26% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Shanxi C&Y Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanxi C&Y Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Shanxi C&Y Pharmaceutical Group Co Ltd (2013–2014)

The table below shows the annual Asset Resilience Ratio data for Shanxi C&Y Pharmaceutical Group Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2014-12-31	1.84%	CN¥21.76 Million ≈ $3.18 Million	CN¥1.18 Billion ≈ $172.87 Million	+1.81pp
2013-12-31	0.04%	CN¥388.94K ≈ $56.91K	CN¥1.09 Billion ≈ $159.56 Million	--

pp = percentage points

About Shanxi C&Y Pharmaceutical Group Co Ltd

SHE:300254 China Drug Manufacturers - Specialty & Generic

Market Cap

$347.72 Million

CN¥2.38 Billion CNY

Market Cap Rank

#14252 Global

#4287 in China

Share Price

CN¥9.28

Change (1 day)

-0.11%

52-Week Range

CN¥9.10 - CN¥14.68

All Time High

CN¥31.09